Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma

Overview

Journal Ann Surg

Specialty General Surgery

Date 2016 Oct 21

PMID 27759618

Citations 74

Authors

Jun H Lee

Kevin K Chang

Changhwan Yoon

Laura H Tang

Vivian E Strong

Sam S Yoon

Affiliations

Soon will be listed here.

Abstract

Objective: To examine sites of initial recurrence in patients after resection of gastric and gastroesophageal junction Siewert II/III adenocarcinoma (GA).

Background: There are few recent studies on recurrence for Western patients following potentially curative resection of GA.

Methods: A review of a prospectively maintained, single institution database was performed. Clinicopathologic factors, site(s) of initial recurrence, disease-free survival, and overall survival were examined.

Results: From January 2000 to June 2010, 957 patients underwent potentially curative resection for GA, 435 patients (46%) had recurrent disease, and complete data on recurrence site(s) could be obtained in 386 patients. Tumors were Lauren intestinal type in 206 (53%) and diffuse or mixed-type in 180 (47%). Median time to recurrence was 12 months and 75% of recurrences occurred within 2 years. There was a significant difference in pattern of initial recurrence between the intestinal and diffuse/mixed cohorts (P < 0.001). For intestinal tumors, distant metastasis was the most common site (54%), followed by locoregional (20%), peritoneal (15%), and multifocal (11%). For diffuse/mixed tumors, peritoneal recurrence was the most common (37%), followed by distant (32%), locoregional (22%), and multifocal (9%). On multivariate analysis, Lauren histologic type was the only significant factor that was associated with both peritoneal recurrence (diffuse, hazard ratio 2.22, confidence interval 1.38-3.94) and distant recurrence (intestinal, hazard ratio 1.888, confidence interval 1.202-2.966). After recurrence, median overall survival was only 8.4 months.

Conclusions: In GA patients who recur after resection, patterns of recurrence vary significantly based on Lauren histologic type.

Citing Articles

Prognostic Impact of Fluorescent Lymphography on Gastric Cancer After Neoadjuvant Chemotherapy.

Tang Y, Huang Z, Sun Y, Zhao Y, Qiu W, He J JAMA Surg. 2025; .

PMID: 40072431 PMC: 11904804. DOI: 10.1001/jamasurg.2025.0108.

Development of a prognostic oxidative stress-immune-inflammation score and online calculators for predicting survival and recurrence in gastric cancer: a multicenter study.

Zheng H, Zheng H, Du X, Xu B, Hu M, Yu J Surg Endosc. 2025; .

PMID: 40050495 DOI: 10.1007/s00464-025-11596-6.

Preoperative prediction of the Lauren classification in gastric cancer using automated nnU-Net and radiomics: a multicenter study.

Cao B, Hu J, Li H, Liu X, Rong C, Li S Insights Imaging. 2025; 16(1):48.

PMID: 40000513 PMC: 11861772. DOI: 10.1186/s13244-025-01923-9.

Mutant Pattern of p53 as a Feasible Predictor of Distant Metastasis Following Curative Gastrectomy for Advanced-stage Gastric Cancer.

An Q, Miao L, Wu J, Ma J J Cancer. 2025; 16(3):860-875.

PMID: 39781338 PMC: 11705056. DOI: 10.7150/jca.98563.

Using artificial intelligence and statistics for managing peritoneal metastases from gastrointestinal cancers.

Wojtulewski A, Sikora A, Dineen S, Raoof M, Karolak A Brief Funct Genomics. 2024; 24.

PMID: 39736152 PMC: 11735730. DOI: 10.1093/bfgp/elae049.

References

Spolverato G, Ejaz A, Kim Y, Squires M, Poultsides G, Fields R . Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg. 2014; 219(4):664-75. DOI: 10.1016/j.jamcollsurg.2014.03.062. View

Wagner A, Grothe W, Haerting J, Kleber G, Grothey A, Fleig W . Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24(18):2903-9. DOI: 10.1200/JCO.2005.05.0245. View

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36-46. DOI: 10.1056/NEJMoa073149. View

Kim S, Lim D, Lee J, Kang W, Macdonald J, Park C . An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005; 63(5):1279-85. DOI: 10.1016/j.ijrobp.2005.05.005. View

Suh Y, Han D, Kong S, Lee H, Kim Y, Kim W . Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? A comparative analysis according to the seventh AJCC TNM classification. Ann Surg. 2012; 255(5):908-15. DOI: 10.1097/SLA.0b013e31824beb95. View

Rosa F, Marrelli D, Morgagni P, Cipollari C, Vittimberga G, Framarini M . Krukenberg Tumors of Gastric Origin: The Rationale of Surgical Resection and Perioperative Treatments in a Multicenter Western Experience. World J Surg. 2015; 40(4):921-8. DOI: 10.1007/s00268-015-3326-8. View

Baiocchi G, Kodera Y, Marrelli D, Pacelli F, Morgagni P, Roviello F . Follow-up after gastrectomy for cancer: results of an international web round table. World J Gastroenterol. 2014; 20(34):11966-71. PMC: 4161783. DOI: 10.3748/wjg.v20.i34.11966. View

LAUREN P . THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965; 64:31-49. DOI: 10.1111/apm.1965.64.1.31. View

Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K . Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer. 2011; 130(12):2912-21. DOI: 10.1002/ijc.26330. View

10.

Kinoshita H, Yashiro M, Fukuoka T, Hasegawa T, Morisaki T, Kasashima H . Diffuse-type gastric cancer cells switch their driver pathways from FGFR2 signaling to SDF1/CXCR4 axis in hypoxic tumor microenvironments. Carcinogenesis. 2015; 36(12):1511-20. DOI: 10.1093/carcin/bgv134. View

11.

Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F . Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2013; 40(1):12-26. DOI: 10.1016/j.ejso.2013.10.019. View

12.

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

13.

Wang K, Yuen S, Xu J, Lee S, Yan H, Shi S . Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014; 46(6):573-82. DOI: 10.1038/ng.2983. View

14.

Gunderson L, SOSIN H . Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982; 8(1):1-11. DOI: 10.1016/0360-3016(82)90377-7. View

15.

DAngelica M, Gonen M, Brennan M, Turnbull A, Bains M, Karpeh M . Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004; 240(5):808-16. PMC: 1356486. DOI: 10.1097/01.sla.0000143245.28656.15. View

16.

Japanese Gastric Cancer Association . Japanese Classification of Gastric Carcinoma - 2nd English Edition -. Gastric Cancer. 2002; 1(1):10-24. DOI: 10.1007/s101209800016. View

17.

Jackson C, Cunningham D, Oliveira J . Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 Suppl 4:34-6. DOI: 10.1093/annonc/mdp122. View

18.

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357(18):1810-20. DOI: 10.1056/NEJMoa072252. View

19.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

20.

Bang Y, Kim Y, Yang H, Chung H, Park Y, Lee K . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379(9813):315-21. DOI: 10.1016/S0140-6736(11)61873-4. View